Literature DB >> 10435578

Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical.

Y H Ding1, B M Baker, D N Garboczi, W E Biddison, D C Wiley.   

Abstract

The interactions of three singly substituted peptide variants of the HTLV-1 Tax peptide bound to HLA-A2 with the A6 T cell receptor have been studied using T cell assays, kinetic and thermodynamic measurements, and X-ray crystallography. The three peptide/MHC ligands include weak agonists and antagonists with different affinities for TCR. The three-dimensional structures of the three A6-TCR/peptide/HLA-A2 complexes are remarkably similar to each other and to the wild-type agonist complex, with minor adjustments at the interface to accommodate the peptide substitutions (P6A, V7R, and Y8A). The lack of correlation between structural changes and the type of T cell signals induced provides direct evidence that different signals are not generated by different ligand-induced conformational changes in the alphabeta TCR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435578     DOI: 10.1016/s1074-7613(00)80080-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  124 in total

1.  Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.

Authors:  J Hennecke; A Carfi; D C Wiley
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.

Authors:  Francis K Insaidoo; Oleg Y Borbulevych; Moushumi Hossain; Sujatha M Santhanagopolan; Tiffany K Baxter; Brian M Baker
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 3.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 4.  Mediation of T-cell activation by actin meshworks.

Authors:  Peter Beemiller; Matthew F Krummel
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-08-11       Impact factor: 10.005

5.  How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire.

Authors:  Sydney J Blevins; Brian G Pierce; Nishant K Singh; Timothy P Riley; Yuan Wang; Timothy T Spear; Michael I Nishimura; Zhiping Weng; Brian M Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

6.  Structural basis of affinity maturation and intramolecular cooperativity in a protein-protein interaction.

Authors:  Sangwoo Cho; Chittoor P Swaminathan; Jianying Yang; Melissa C Kerzic; Rongjin Guan; Michele C Kieke; David M Kranz; Roy A Mariuzza; Eric J Sundberg
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

7.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

8.  TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility.

Authors:  William F Hawse; Soumya De; Alex I Greenwood; Linda K Nicholson; Jaroslav Zajicek; Evgenii L Kovrigin; David M Kranz; K Christopher Garcia; Brian M Baker
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

Review 9.  Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy.

Authors:  Scheherazade Sadegh-Nasseri; Sarat K Dalai; Laura C Korb Ferris; Saied Mirshahidi
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

Review 10.  Cross-reactivity of T lymphocytes in infection and autoimmunity.

Authors:  Thomas Kamradt; Rudolf Volkmer-Engert
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.